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Introduction: Improving evidence informed decision-making in immunisation is a global health priority
and many low and middle-income countries have established National Immunisation Technical
Advisory Groups (NITAGs) as independent technical advisory bodies for this purpose. NITAG develop-
ment and strengthening has received financial and technical support over the past decade, but relatively
little evaluation. This study examined NITAGs in six low and middle-income countries (i.e. Armenia,
Ghana, Indonesia, Nigeria, Senegal, Uganda), to examine functionality, quality of recommendation devel-
opment, and integration with national decision-making bodies and processes.
Methods: A mixed-method case-series design, used semi-structured interviews, NITAG meeting observa-
tions, and document review. Data were analysed thematically.
Results: Five NITAGs had been legally established with terms of reference and appeared well functioning,
with Ghana’s in development. All NITAGs had standard operating procedures and nomination procedures
to ensure a range of expertise, generally comprising 10–15 core, 1–5 secretariat, and several ex-officio
members. Aside from economics, NITAGs reported a wide range of member expertise. Newer NITAGs
had particular concerns about funding. Four used formal conflict of interest procedures, although some
commented that implications were not always understood. NITAGs valued local data, and limited evi-
dence suggested NITAG presence might reinforce data production through surveillance and local research
studies. All observed meetings demonstrated due process and evidence-based decision-making processes
were generally followed, with a critical role played by working-group data syntheses and assessments.
NITAGs were seen as well integrated with ministry of health (MoH) decision-making and MoH intervie-
wees were positive about NITAG contributions, indicating NITAGs had an important role. Collaboration
with other bodies was more limited, but mitigated by NITAG members’ cross-membership in other
bodies.
Conclusions: NITAGs have an important and valued role within national immunisation decision-making.
However, their position remains insecure, with the need for sustainable technical and financial support.
 2018 Published by Elsevier Ltd.
1. Introduction
Improving immunisation decision-making and national policy
development through better evidence use is a global health
priority [1]. Many low and middle-income countries (LMICs) have
followed high-income countries in establishing National Immuni-
sation Technical Advisory Groups (NITAGs). NITAGs provide
independent technical guidance to national policy-makers and
programme managers to support evidence-based and locally-
relevant immunisation policy and programme decisions [2,3].
Effective NITAGs are thus a global immunisation priority, and a
marker of countries’ immunisation commitment, since the Global
Vaccine Action Plan 2011–2020 called all countries to establish
or have access to NITAGs by 2020 [1].
Since 2009, the World Health Organization (WHO) and Unicef
included NITAG presence and six functionality indicators in annual
immunisation Joint Reporting Forms (JRF): (i) formal written terms
of reference; (ii) legislative or administrative basis for establishing
the NITAG; (iii) core membership of at least five expertise areas
(i.e. epidemiology, immunology, infectious diseases, paediatrics,
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public health); (iv) at least one meeting annually; (v) agenda and
background materials distributed ahead of meetings; and (vi) dec-
laration of interests by NITAG members [4,5]. By late 2016, 125 of
194 WHO member states reported having a NITAG, 120 (96%) of
which were officially legislated - including 22 low-income and
69 middle-income countries. Ninety (46%) reported their NITAG
complying with all six JRF indicators, including 6 low-income
and 46 middle-income countries [6].
Despite NITAGs’ recognised value for national decision-making
[7,8], relatively little independent analysis has been published.
While several articles examined NITAG functioning and working
processes, using data from international meetings and self-
assessment, more can be learned from NITAGs and their challenges
[8–13]. As part of external evaluation of SIVAC (Box 1), a ten-year
global initiative to develop and strengthen LMIC NITAGs [13–15],
this study examines NITAG implementation, particularly function-
ality, quality, and integration in Armenia, Ghana, Indonesia,
Nigeria, Senegal, and Uganda. Though Ghana’s NITAG was not yet
established, it was included as a case because its development
received considerable external support, particularly from SIVAC.
2. Methods
2.1. Study design
We chose a mixed-methods case-series design, including semi-
structured key informant interviews, meeting observations, and
documentary analysis. Six case-study countries were selected
based on LMIC status, feasibility (e.g. access, language, security),
and to provide a range of: (i) regions, i.e. Africa, Asia, Europe; (ii)
NITAG operation length; and (ii) eligibility for Gavi support, i.e. eli-
gible, transitioning from support [16]. All cases received some
SIVAC support to develop or strengthen capacity [13,17].
2.2. Data collection
We recruited interviewees purposively, based on roles and
knowledge, from NITAG core, secretariat, and ex-officio members
(i.e. advisory members, by virtue of institutional position or affili-
ation – such as UN or NGO representatives, with no voting rights);
government staff, including national immunisation programme
and ministry of health (MOH) officials; and external partners
involved in immunisation policy (e.g. WHO, Unicef). Most inter-
views were conducted face-to-face, during country visits, or via
telephone and Skype. Interviewees provided written informed con-
sent prior to interviews, which were audio recorded and profes-
sionally transcribed. We ensured anonymity by removing
personal identifiers. We included 56 interviewees, i.e. 5 for Arme-
nia, 8 for Ghana, 13 for Indonesia, 12 for Nigeria, 9 for Senegal, and
9 for Uganda during 2017 (Table 1).
We observed NITAG meetings in five countries. Ghana’s NITAG
was not yet established and thus not visited. The observation tem-
plate was designed to ensure inclusion of relevant issues (e.g.
members and roles, evidence appraisal, decisions) while including
emergent issues. Meetings were conducted in English, except in
Armenia and Indonesia, which were translated professionally and
notes taken simultaneously.
We reviewed technical reports, administrative documents (e.g.
NITAG Standard operating procedures, meeting minutes), and
NITAG outputs (e.g. recommendations).
2.3. Analysis
We analysed data thematically using NITAG Evaluation Tool cat-
egories [18]: (i) functionality; (ii) quality of processes and outputs;
(iii) integration with national decision-making (Table 2). We did
not evaluate individual NITAGs, instead examining NITAG roles,
challenges, and achievements overall.
2.4. Ethics
The London School of Hygiene and Tropical Medicine Observa-
tional Research Ethics Committee provided approval (reference
12036).
3. Results
3.1. Functionality
NITAG structural viability: All five NITAGs had been legally estab-
lished with developed terms of reference (TORs). In addition to
advising MoH on new vaccines, some interviewees suggested
expanding NITAG TORs to advising national vaccination pro-
grammes (e.g. Indonesia, Senegal, Uganda) on technical and cost-
effectiveness issues, with one describing the NITAG as a ‘think-
tank’ for the vaccination programme.
‘‘...if we start [vaccine implementation] and then funding
becomes a problem, you’ll find you have started on something
which you cannot carry on, and this is the big role that we have
given NITAG to advise us...” (Uganda#5)
While Ghana was slow to establish a NITAG, challenges to
national vaccination programme sustainability appeared to gener-
ate renewed interest in its NITAG, after years of delay.
‘‘I believe that the government, the minister, and the ministry
are very interested in setting-up the NITAG, and especially so
with the transitioning from Gavi support” (Ghana#5)
Other NITAG roles included providing credibility, raising public
immunisation awareness, engaging with healthcare professionals,
and acting as referee or technical resource in response to rumours
or hesitancy. For example, ITAGI (Indonesia) regularly developed
recommendations addressing community anti-vaccine sentiment.
Nigerian interviewees noted that a NITAG could have avoided or
mitigated the ‘polio controversy’ [19]. A positive initiative for UNI-
TAG (Uganda) was contributing to the passing of a national immu-
nisation law. A crucial NITAG role was in emphasising a shift to
transparent, impartial and inclusive decision-making from reliance
on a few expert opinions for national immunisation programmes.
Newer NITAGs (e.g. Nigeria, Uganda, Senegal) expressed con-
cerns about lacking guaranteed funding, while all advocated
increasing the reliable funding of secretariats. Established NITAGs
(e.g. Armenia, Indonesia) relied predominantly on government
funding for running costs, which were kept relatively low (e.g.
The SIVAC Initiative (2008–2017) provided technical support for establishing and strengthening NITAGs in low and middle-income countries [15]. Funded primarily
by the Bill & Melinda Gates Foundation, through the Agence de Médecine Préventive (AMP) in collaboration with the International Vaccine Institute (IVI), the SIVAC
Initiative provided some degree of support to 43 countries. It worked more extensively in 30 of these countries. Major SIVAC activities were advocacy, direct tech-
nical - and sometimes financial - support to countries, and development of training materials. Advocacy was a large component of SIVAC’s work, particularly during
the initial years. SIVAC worked to raise the profile of NITAGs in the global agenda, through collaboration with academic institutions, participating in conferences
and partner meetings, and publishing articles [12,13].
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Table 1
NITAG descriptions and recent recommendations.
NITAG Statusa JRF 2017 Meetings and Working
Groups (WGs)b
Examples of recent recommendations NITAG background and description
Armenia
Est. 2013
Region:
EURO
Income:
L-MIC
Gavi:
Tran 2
Functional
(5/6,
except CoI
process)
Annual meetings:
4 (2016)
4 (2015)
2 (2014)
WGs: 2 (i.e. HPV,
influenza)
Meeting observed: June
2017
Recommendation on HPV vaccine introduction
(2017): the NITAG supported the MoH Gavi
application, based on consideration of the
public health importance of cervical cancer in
Armenia, data on efficacy and effectiveness
and preliminary impact data from other
countries. However, it recommended a
demonstration project in 11 districts first to
refine communications strategies and explore
costs.
Developing national influenza vaccination
strategy:
In response to MoH request, due to issues
with changing funding levels and target
populations.
Replaced a similar committee established in
2009. A 2015 evaluation indicated that it was
functional, although not fully compliant with
best practices (e.g. lack of CoI policy, lack of
SOPs, no liaison or ex-officio officers, unclear
agenda-setting process, unclear
recommendation development framework).
No MoH budget was allocated and operating
costs were minimal. Armenia fulfilled all JRF
criteria, except for members declaring
conflicts of interest, since 2013. Four NITAG
meetings were held in 2015 and five in 2016.
Working groups were first established to
review HPV vaccine introduction in 2016 and
influenza vaccination policy in 2017.
Ghana
Est: No
Region:
AFRO
Income:
L-MIC
Gavi:
Tran 1
NA (0/6) Annual meetings:
None yet
WGs: None
Meeting observed: No
None Began development in 2013. SIVAC, a global
NITAG support initiative (2007–2017),
conducted an assessment visit in late 2011
and supported development of a concept note
issued in May 2013. Potential members were
identified in 2015. However, political changes
affected progress, with three minister of
health between 2015 and 2017, disease
outbreaks, lack of funding clarity,
organisational divisions between the Ministry
of Health and the Ghana Health Service, and
confusion amongst some stakeholders about
differences between NITAG and Inter-Agency
Coordinating Committee (ICC).
Indonesian
Technical
Advisory
Group on
Immunisation
(ITAGI)
Est. 2007
Region:
SEARO
Income:
L-MIC
Gavi:
Tran 2
Functional
(6/6)
Annual meetings:
3 (2016)
7 (2015)
3 (2014)
WGs: As needed
Meeting observed: April
2017
Recommendation on dengue vaccine
introduction (2018): Responding to a 2016
MoH request on the new dengue vaccine,
ITAGI began discussions and expect to make a
recommendation in early 2018.
Recommendation on Measles-Rubella vaccine
introduction (2016): ITAGI recommended that
MoH implement a catch-up campaign of
rubella vaccination combined with measles
vaccination, targeting 9mo-15y, followed by
routine immunisation for all infants.
Recommendation on Japanese Encephalitis
vaccine in Bali Province (2016): ITAGI
recommended that MoH introduce JE vaccine
with a ‘crash programme’ in one of the most
endemic and strategic provinces, with the
most complete JE data on JE, and use results to
develop strategic plans in 3 other high
endemicity provinces.
The oldest, it was established as an
independent advisory committee to the
national immunisation programme and MoH,
replacing another expert committee
performing a similar function. It has fulfilled
all JRF criteria since recording began in 2010.
It consists of approximately 3 secretariat and
18 core members from a range of disciplines.
It has comprehensive SOPs and holds 4
meetings annually, plus provision for more
frequent smaller meetings. Funding comes
from MOH, Gavi, and a small amount from
WHO. Meeting travel and accommodation are
covered, but staff are unpaid with the
exception of one support person.
Nigerian
Immunisation
Technical
Advisory
Group
(NGI-TAG)
Est. 2015
Region:
AFRO
Income:
L-MIC
Gavi:
Tran 1
Functional
(6/6)
Annual meetings:
4 (2017)
0 (2016)
2 (2015)
WGs: 7 (i.e.
cerebrospinal
meningitis, polio,
measles, rotavirus, HPV,
tetanus, yellow fever)
Meeting observed: Sep
2017
Recommendation on introducing meningitis
vaccine (2017): MoH requested a
recommendation on whether and which
meningitis vaccine to introduce into routine
immunisation. After review and discussion of
WG findings, NGI-TAG recommended the
introduction of MCYW vaccine by 2022, and
in the interim to use MenAfriVac as less
effective but more affordable for routine
introduction.
The youngest, inaugurated on 17 August
2015, by the Permanent Secretary of the
Federal Ministry of Health (FMOH), and is
hosted by the National Primary Health Care
Development Agency, a parastatal of Nigeria’s
FMOH. The NGI-TAG developed
comprehensive standard operating
procedures (the ‘‘Green Book”) and conflict of
interest procedures and aims to meet
quarterly. Initial lack of funds prevented NGI-
TAG or working group meetings until 2017.
The NITAG has fulfilled all JRF criteria since
2015. Seven vaccine working groups were
initially organised for cerebrospinal
meningitis, polio, measles, rotavirus, human
papilloma virus, tetanus, and yellow fever.
SIVAC supported training of some members
through a workshop and vaccinology course
and on-the-job guidance.
(continued on next page)
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member time was donated, capacity-building and international
travel was minimal and/or externally funded). NITAGs shared chal-
lenges in mobilising sustainable government and/or external fund-
ing. Ensuring funding mechanisms did not jeopardise NITAG
independence was a concern identified in some countries (e.g.
Nigeria). Several had received significant external operational sup-
port – through, for example, SIVAC or WHO, for funding of secre-
tariat, meetings, and/or trainings (e.g. Indonesia, Senegal,
Uganda), joint work-plan development, or development of specific
recommendations (e.g. Nigeria, Senegal, Uganda), raising concerns
about sustainability (e.g. Nigeria, Uganda, Senegal) after this sup-
port ended. Some CCVS (Senegal) members indicated that given
minimal support of basic running cost by government and/or
WHO and additional training on evidence review and vaccinology,
it could continue to work effectively. UNITAG members acknowl-
edged that Uganda’s MoH should take more ownership of UNITAG
funding, but given MoH constraints and priorities, this was not
considered an immediate solution to anticipated needs for long-
term financial and capacity-building support.
‘‘Members operate on a three year tenure and our first tenure is
expiring at the end of this year, so we’re going to get maybe 40%
new members starting next year and the whole process has to
start again to try and get them to understand what needs to
be done.” (Uganda#3)
Functional capacity: All NITAGs had Standard Operating Proce-
dures (SOPs) and nomination procedures to ensure a relevant
range of expertise. NITAGs generally comprised 10–15 core mem-
bers (including chair and deputy), 1–5 secretariat, and several ex-
officio members. Core members covered the five JRF expertise
areas (i.e. epidemiology, immunology, infectious diseases, paedi-
atrics, public health) and identified specialities, e.g. microbiology,
neurology, and health policy. Clinical specialties dominated mem-
bership. The Secretariat, often seconded from national immunisa-
tion programmes, provided administrative and technical support
and linkages with MoH. Ex-officio observers included MoH and
donor and technical partners (e.g. WHO, Unicef, Sabin). Thus,
NITAG meetings could have 20–30 people attending. Members’
professional recognition and expertise was valued because of tech-
nical benefits but also as reinforcing NITAG credibility nationally.
Those operating for several years indicated members had a good
understanding of how to conduct activities and deliver recommen-
dations. All NITAGs reported an appropriate range of expertise,
with the exception of economic evaluation, and in one case legal
expertise, as members were generally less familiar with these tech-
nical areas and they were not included as expectations in JRF
reporting.
All NITAGs reported that planning included developing annual
work-plans. Four NITAGs had working-groups of 5–7 members
Table 1 (continued)
NITAG Statusa JRF 2017 Meetings and Working
Groups (WGs)b
Examples of recent recommendations NITAG background and description
Senegal Comite
Consultatif
pour la
Vaccination au
Senegal
(CCVS)
Est. 2013
Region:
AFRO
Income:
LIC
Gavi:
Tran 1
Functional
(6/6)
Annual meetings:
3 (2016)
3 (2015)
3 (2014)
WGs: 2–3, as needed
Meeting observed: April
2017
Recommendation on introducing birth-dose
Hepatitis B vaccination: The recommendation
to introduce the Hep B vaccine at birth and
adopt the WHO recommendation by giving a
longer time window to vaccinate – within 72
h with a view to reach out to children that are
not delivered in health care facilitate, and
prepare a tailored introduction plan for each
district
Recommendation on introducing Menafrivac
vaccine into routine immunisation: Analysis of
local epidemiological data, including
organising a national surveillance workshop,
showed that after 2012 and 2013 mass
campaigns, MenA cases virtually disappeared
while numbers of other valents grew steadily.
As Senegal will transition from Gavi support
soon, CCVS recommended, after extensive
discussion, to introduce 1 dose at 15mo,
invest in strengthening surveillance, review in
2019 and consider shifting to a quadrivalent
vaccine.
Senegal’s NITAG was established
approximately two years after initial
development discussions (Jan 2012). The
rationale described in official documents
mention improving the quality of the decision
making process and the need to ‘‘take better
account of local specifics of vaccination”. The
NITAG’s scope was wide ranging, aiming to
oversee and monitor immunisation policy and
programme, provide technical and scientific
expertise, establish partnerships with
national and international bodies, and
advocate for immunisation. The NITAG has
fulfilled all JRF criteria since 2014. A review of
2014–2016 work-plans showed that a
majority of technical activities were
implemented, notably those related to
specific vaccine recommendations. Some
recommendations were postponed, e.g.
strategic review of the immunisation
programme and a review of the NITAG
sustainability strategy were postponed
because of challenges in organising meetings,
unexpected priorities (e.g. Ebola), and lack of
secretariat staff availability.
Ugandan
National
Immunisation
Technical
Advisory
Group
(UNITAG)
Est. 2014
Region:
AFRO
Income:
LIC
Gavi:
Eligible
Functional
(6/6)
Annual meetings:
4 (2016)
3 (2015)
0 (2014)
WGs: 5 (i.e. new vaccine
priorities, MenA,
rotavirus, influenza,
malaria)
Meeting observed: April
2017
Recommendation on introducing Rotavirus
vaccine (2015): The UNITAG WG presented a
technical report to a plenary of members in
August 2014 and following discussion, core
members submitted the consensus opinion
that Rotavirus vaccine should be introduced
into Uganda’s routine immunisation program
subject to availability of sustainable
government financing.
Recommendation on introducing MenAfriVac
vaccine (2015): UNITAG recommended that
MenAfriVac vaccine be limited to campaigns
in high-risk districts in Northern and Western
Uganda and that proposals for introduction
into routine immunization or catch-up
campaigns be considered separately.
Replaced the Ugandan Advisory Committee
on Vaccines and Immunization (ACVI), a
similar body established in 2012. ACVI
formation was spearheaded by the Uganda
National Academy of Sciences (UNAS), which
became UNITAG Secretariat. UNITAG aims are
wide ranging, including providing technical
and scientific expertise to the government
and advising national immunisation policy
and programme implementation. It has
fulfilled all JRF criteria since 2015.
NB: aGavi eligibility, LMIC status, and JRF status were assessed for 2017; ‘Tran 1’ and ‘Tran 2’ refer to Gavi’s funding transition phases [23]. b’Meetings’ refers to numbers or
average number of annual meetings; ‘WGs’ refers to number of working-groups; ‘Observed’ refers to if and when the NITAG was observed.
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Table 2
NITAG assessmenta criteria, categories, challengesb, and findings.
Criteria Description Assessment categories NITAG challenges
identified by WHO-
SAGE, April 2017b
Case study findings (excluding Ghana)
Functionality Functional NITAG structure and
operations, fostering timely
generation of recommendations.
 Structural viability(i.e. whether NITAG
has been legally established with speci-
fic TORs and guaranteed resources for
routine functioning)
 Lack of secretariat;
 Funding concerns;
 Most were functional, with specific
TORs;
 Some had funding sustainability con-
cerns (e.g. secretariat funding);
 Willingness to expand TORs to pro-
gramme steering, sustainability
assessment, and issues beyond vac-
cine introduction.
 Functional capacity(i.e. having and com-
plying with formalised and approved
SOPs, member nomination procedures,
and areas of expertise; whether activity
planning and execution include formal
work-plans and working groups;
whether NITAG has formal reporting
obligations to MoH; existence and use
of a formal COI policy, and conse-
quences of declared interests.)
 Lack of SOPs and
work-plans;
 Instability;
 Inadequate proce-
dures (e.g. COI).
 All had approved SOPs and work-
plans;
 Less-supported NITAGs (e.g. lacking
technical support/training) appeared
less functional/sustainable;
 Reporting obligations to MoH varied;
 Four had formal COI procedures,
though one reported implementation
challenges;
 No consequences of declared inter-
ests were observed.
 Productivity(i.e. number of recommen-
dations issued, whether these were part
of work-plans and within expected
timeframes, and how NITAGs
responded to any urgent MoH requests)
 Lack of annual
work-plans.
 Variation in numbers of recommen-
dations produced and taken up by
MoH, largely due to differences in
maturity and funding levels.
Quality NITAG capacity and quality of
data collection, analysis, and
synthesis processes, evidence and
data needed to deliver
recommendations.
 Human resource capacity(i.e. whether
secretariat have necessary technical
skills; members have opportunities to
build their capacity to use scientific evi-
dence; the NITAG is able to access
external technical expertise, interna-
tional and national scientific data as
needed; and how working-groups are
mandated and coordinated, members
nominated, and outputs reported)
 Lack of expertise
and training.
 Secretariat training and technical
skills varied, depending largely on
external support levels;
 Evidence of access to technical
expertise and scientific data, to dif-
ferent degrees;
 Working-groups were operational
and produced evidence-based
reports, though numbers, mandate,
coordination, and member nomina-
tion procedures varied.
 Analytical process quality(i.e. whether
and how members apply specific
frameworks to defining policy issues,
research questions, type/importance of
data, and data collection; howmembers
synthesise evidence and assess quality;
and how recommendations are
decided)
 No formalised
processes.
 Formal processes existed and
appeared to be followed.
 Outputs quality(i.e. whether recommen-
dations include a standardised sum-
mary of development process and
technical questions addressed)
 NA  Evidence of good quality reviews,
particularly among NITAGs that
received external training.
Integration Integration and recognition
within the national decision-
making system.
 Transparency(i.e. whether governing
policies were publically available; non-
member participation; and how stake-
holder concerns were addressed)
 NA  NITAG governance policies and docu-
mentation were available, though
not all NITAGs had their own web
presence, and some used the NITAG
Resource Centre;
 Non-member observation was
supported;
 Unclear how stakeholder concerns
addressed.
 Interaction with national stakeholders(i.e.
frequency, format, channel, formality,
and focal person for communication
with MoH, stakeholders, and public;
national immunisation collaborators
and perceived antagonisms; and partic-
ipation in relevant fora)
 External partner
processes not
involving NITAG;
 NITAG activities
not in country
plans.
 Interactions with other bodies (e.g.
ICC) varied and were mostly
informal;
 Integration was an area in which
most NITAGs required further
progress.
 Acknowledgement by nationally-rele-
vant parties(i.e. awareness of NITAG
existence and role by decision-makers,
implementers, and public; take-up of
recommendations by MoH; whether
members were called as resources;
and whether other organisations dis-
seminated NITAG recommendations)
 Confusion with
other bodies (e.g.
ICC, HTA);
 Low awareness of
NITAG role.
 Recommendations issued and
reportedly adopted by MoH;
 Members were considered national
experts and called as resources,
though it was unclear whether this
related to NITAG affiliation;
 Some NITAGs had recommendations
disseminated.
NB: aEvaluation framework adapted from [18]. bIncluded a broad range of NITAGs [24].
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developing specific recommendations (Table 1). The Armenian
NITAG, which had received minimal external support, was report-
edly still strengthening operating procedures and initiating
working-groups for specific vaccines (e.g. HPV, influenza) [20].
While most NITAGs had reporting obligations, the format and for-
mality of these varied.
Most NITAGs used formalised conflict of interest (COI) proce-
dures, although some commented that implications were not
always understood.
‘‘We use it [COI form] but whether we give it the attention it
deserves I think is another matter. I think many people, just
as a knee-jerk reflex may sign not really understanding the full
implication of what they have done by signing the form.”
(Nigeria#7).
Actual consequences of declaring interests remained unclear, as
no interviewees described examples of interests being declared.
Productivity: Table 1 shows recent recommendations. Work-
plan agendas were either set entirely by MoH (e.g. Nigeria, Senegal,
Uganda) or in collaboration with NITAGs (e.g. Armenia, Indonesia),
which were generally very responsive to MoH requests. Time-
frame issues remained unclear, as several NITAGs were new and
financially constrained in the years preceding the study. However,
all reported issuing recommendations within agreed timeframes
(e.g. Nigeria issued its first in 2017).
3.2. Quality
Human resources capacity and data access: A strong secretariat
was considered essential to NITAG functioning. As several NITAGs
relied on secretariat who were seconded part-time from national
programmes, capacity and relevant technical skills were some-
times problematic. Member opportunities to strengthen their
capacity to collect, synthesise and analyse evidence in decision-
making also varied, primarily on the amount of external technical
support available.
NITAGs valued local data, and limited evidence suggested
NITAG presence might reinforce data production through surveil-
lance and local research studies. NITAG members noted that local
data might not always be available or of sufficient quality for
decision-making, and were generally pragmatic about using the
best-quality data that was accessible. Members typically used uni-
versity and hospital affiliations, and/or links with local partners, to
source non open-access literature and local evidence. Using local
data and context to tailor WHO-SAGE recommendations was iden-
tified as a key value of NITAGs. For example, Armenian intervie-
wees noted the importance of reviewing local influenza
vaccination target groups, as these were often modified depending
on funding source (i.e. external, governmental), leading to health-
worker confusion.
‘‘We prefer the local data of course, because the local data
explain the characteristics of our country. So, that’s why we
are strengthening the surveillance.” (Indonesia#23)
‘‘Senegal has adopted the recommendation to suit its local con-
text and ensure better feasibility. The WHO was recommending
24 hours [for HepB birth-dose] but Senegal decided to advise
vaccination within 72 hours of birth [as most births occurred
at home]... The role of the committee is to make sure that the
WHO recommendation is applicable in Senegal.” (Senegal#8)
While working-group mandates were relatively consistent,
coordination, nomination, and output reporting could be further
systematised.
Analytical process quality: All meetings observed showed a high
degree of due process and, despite some weaknesses, that an
evidence-based decision-making process was followed, with a crit-
ical role played by working-group data syntheses and assessments.
Plenary discussions were observed as very active and of generally
good quality. Evidence from working-group documentation (e.g.
Uganda, Indonesia, Senegal) showed that literature was exten-
sively reviewed, and local data and cost implications integrated
into analyses. Several NITAGs used new vaccine ‘piloting’ to gather
additional evidence, notably on cost-effectiveness, before scaling-
up nationally (e.g. Armenia, Indonesia). However, all but UNITAG
and ITAGI indicated limited consideration of economic evaluation
in decision-making, a particularly important issue in countries
approaching Gavi transition (e.g. Armenia, Nigeria).
Outputs quality: NITAGs had varying degrees of standardisation
of recommendations, with UNITAG producing particularly well-
structured outputs. This included variation in publication of review
and evidence synthesis results, with not all routinely disseminat-
ing the scientific rationale behind their recommendations.
3.3. Integration
Transparency: While most NITAG members appeared willing to
share governance documents, most did not have websites, though
some shared recommendations through the NITAG Resource Cen-
tre (http://www.nitag-resource.org/). All allowed non-member
observers by prior arrangement. Methods of addressing stake-
holder concerns varied, depending on the nature of concerns (e.g.
policy, technical, role) and was often through advising MoH.
Interaction with national decision-makers and stakeholders: Inter-
action format and channels varied, but were usually through chair-
persons and/or secretariat. Interviewees noted collaboration with
national decision-making bodies (e.g. ICC - interagency coordinat-
ing committee, national regulatory authority) as important, but not
always well defined or understood, and sometimes reflecting a
fragmented institutional landscape. This was potentially worsened
by parallel committees overseeing vertical programmes (e.g. polio
national certification committees) and sometimes mitigated by
NITAG members’ cross-memberships in other bodies (e.g. Senegal,
Uganda). In countries without ICCs (e.g. Indonesia), it was noted
that NITAGs had a more pivotal technical role.
Acknowledgement by national parties: Successful and mature
NITAGs were more fully integrated within national decision-
making processes and valued by MoH. MoH interviewees were
generally very positive about NITAG contributions, indicating it
had an important role. However, interviewees acknowledged that
NITAGs operate within political environments (e.g. resources avail-
able, public vaccine demand, presence of local manufacturers) and
that MoH based decisions on factors additional to research evi-
dence. MoH acknowledgement and awareness of NITAG roles/
responsibilities appeared limited in Armenia and Ghana, both Gavi
transitioning countries. In some case, NITAGs provided technical
support for MoH to resist political pressures to introduce new vac-
cines, e.g. due to costs and/or effectiveness limitations.
‘‘I know the ITAGI is already good [...] They always ask, they try
to understand. If they don’t understand, they will say ‘OK, we
need time to understand this’. And then they will ask questions
to make them understand, and then they will review some
more evidence, if required. So it is back and forth, back and
forth. Only for immunisation is evidence-based decision-
making process working, because of the ITAGI.” (Indonesia#24)
Members and MoH alike indicated that recommendations were
considered, although funding was not always available for imple-
mentation. For example, Armenia produced 4–5 recommendations
in the past two years, all of which were adopted by MoH. Indonesia
produced 5, which were also successfully adopted. Senegal and
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Uganda each produced 3, some of which have already been
accepted, and Nigeria recently produced its first recommendation.
However, NITAGs sometimes produced recommendations for
which MoH decisions had already been made, e.g. to submit a Gavi
application. Integration within MOH processes was seen as essen-
tial by NITAG members, not only to ensure that evidence-based
decision-making could be built into the process but also because
this contributed to building recognition and motivation for NITAG
members and brought credibility to the whole vaccination
programme.
‘‘Without the committee, they would have to ask individual
experts, and this would be less independent and formalised. It
would also be less efficient. For example, it took years for one
person to advocate for the introduction of HepB birth-dose,
including lobbying the first lady [...]. With the committee it
had more weight.” (Senegal#1)
NITAGs were described by interviewees as an instrument of
ownership at country level. In several examples, NITAGs capaci-
tated countries to respond to partner ‘offers’ (e.g. of funding for
specific vaccines) based on local evidence and needs. This was
identified as increasing ability to push back against ‘felt pressure’
from manufacturers and funding partners.
‘‘WHO was pushing us at country level to introduce the [Mena-
frivac] vaccine, but the CCVS said ‘‘No, let’s wait”.... They said
serotypes and vaccines were not aligned.” (Senegal#6)
4. Discussion
NITAGs were described as instruments of country ownership,
which could use evidence to tailor immunisation investments to
country-specific epidemiology and health systems, thus enhancing
financial sustainability. They were perceived as helping resist
external pressures to rapidly introduce less relevant or unsustain-
able vaccines and described in several countries as examples of
good practices that other national programmes should use. The
importance of national ownership of vaccine introduction reflected
findings from Ba-Nguz et al, who described it as ‘‘paramount to the
credibility and sustainability of immunisation programmes” [11].
Challenges to functionality were similar across NITAGs, relating
to the difficulty of mobilising unpaid time-constrained experts,
resource constraints, insufficient good-quality local data, some-
times insufficient integration with national decision-making bod-
ies, and comparable with findings by Adjagba et al. [12,21].
However, each NITAG was situated in a specific political, economic
and cultural context. For example, Ghana highlighted political
challenges in establishing a NITAG, while Indonesia, a majority
Muslim country with strong community anti-vaccine sentiment,
highlighted socio-cultural challenges in addressing local sensitivi-
ties around vaccine use.
Findings showed that despite challenges, NITAGs were able to
function satisfactorily in LMICs and provided valuable contribu-
tions to evidence-based decision-making. With adequate technical
support, these NITAGs have gradually progressed from providing
‘expert opinion’ to a formalised and transparent decision-making
process, a key purpose of NITAGs that is increasingly valued by
health ministries. In countries transitioning from Gavi support
(e.g. Ghana, which is currently struggling with planning for contin-
uing to fund a large portfolio of vaccines without Gavi support), a
well-functioning NITAG might help provide the relevant evidence
for programme sustainability. Findings also indicate that NITAGs’
role could extend over time, from steering and reviewing the over-
all immunisation programme, to addressing vaccine confidence
issues and harnessing local research to produce needed context-
specific data.
Findings were based on participant perceptions, and non-
interviewees may have held different views. While the six cases
represent a range of regions and countries, each NITAG exists in
a particularly context and results cannot be directly generalised.
Despite this, findings were generally similar, contributing to
knowledge on NITAG functionality, process quality, and national
integration.
While NITAGs have an important and valued role within
national immunisation decision-making [22], their position
remains somewhat insecure, requiring ongoing technical and in
some cases financial support.
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